Abstract
Background and aim: To determine the temporal evolution of serum markers of autoimmune gastritis, mainly pepsinogen I (PI) and parietal cell antibodies (PCA), in patients with Type 1 diabetes mellitus (DM1). Materials and methods: A 5-yr prospective follow-up study of 168 DM1 patients (87 men, aged 31±9.3 yr) attending the endocrinology outpatient clinic of a university hospital evaluated in 2001 and 2006. Serum PI, gastrin, hemoglobin, cobalamin concentrations, PCA and antibodies to intrinsic factor were measured. Results: In 2001, 11 patients had low PI concentrations and positive PCA (group I), 11 had only low PI concentrations (group II), and 33 had only positive PCA (group III). After 5 yr, PI remained low and PCA positive in all patients from group I. In group II, PI remained low in 4 and normalized in 7. In group III, 4 patients presented low PI concentrations after 5 yr, which remained normal in the other 29 subjects. PCA became negative in 17 patients from group III. In 2001, 3 of the 11 patients of group I had low cobalamin concentrations. In 2006, 2 additional patients from this group presented low cobalamin concentrations. Conclusions: These results show the importance of determining PI together with PCA, since the presence of abnormal results in both tests, that is low PI and positive PCA, is the association that best identifies patients with a higher risk to decrease cobalamin concentrations during follow-up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995, 12: 622–7.
Vitoria JC, Castaño L, Rica I, Bilbao JR, Arrieta A, García-Masdevall MD. Association of insulin-dependent diabetes mellitus and celiac disease: a study based on serologic markers. J Pediatr Gastroenterol Nutr 1998, 27: 47–52.
De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 2008, 93: 363–71.
Barker JM. Clinical review. Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006, 91: 1210–7.
De Block CE, De Leeuw IH, Van Gaal LF. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab 1999, 84: 4062–7.
Irvine WJ, Cullen DR. Natural history of autoimmune achlorhydric atrophic gastritis. Lancet 1974, 31: 482–5.
Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997, 337: 1441–8.
Carmel R. Pepsinogens and other serum markers in pernicious anemia. Am J Clin Pathol 1988, 90: 442–5
Kekki M, Samloff IM, Varis K, Ihamäki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol 1991, 186: 109–16.
Alonso N, Granada ML, Salinas I, et al. Serum pepsinogen I. An early marker of pernicious anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2005, 90: 5254–8.
Davidson RJ, Atrah HI, Sewell HF. Longitudinal study of circulating gastric antibodies in pernicious anaemia. J Clin Pathol 1989, 42: 1092–5.
Riley WJ, Toskes PP, Maclaren NK, Silverstein JH. Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematologic abnormalities associated with insulin-dependent diabetes. Diabetes 1982, 31: 1051–5.
Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982, 83: 204–09.
Alonso N, Granada ML, Salinas I, et al. Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis. Eur J Endocrinol 2007, 157: 763–9.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20: 1161–81.
De Block CE, De Leeuw IH, Bogers JJ, et al. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care 2003, 26: 82–8.
Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T, Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 1990, 25: 513–9.
Ungar B, Stocks AE, Martin FI, Whittingham S, Mackay IR. Intrinsic-factor antibody, parietal-cell antibody, and latent pernicious anaemia in diabetes mellitus. Lancet 1968, 2: 415–7.
Davis RE, McCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Med J Austr 1992, 156: 160–2.
De Block CE, Colpin G, Thielemans K, et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care 2004, 27: 1387–93.
Hirota WK, Zuckerman MJ, Adler DG, et al. Standards of Practice Committee, American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006, 63: 570–80.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alonso, N., Granada, M.L., Soldevila, B. et al. Serum autoimmune gastritis markers, pepsinogen I and parietal cell antibodies, in patients with Type 1 diabetes mellitus: A 5-year prospective study. J Endocrinol Invest 34, 340–344 (2011). https://doi.org/10.1007/BF03347456
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347456